Payment overview · 2025
General Payments
$151.13
9 reported records · 6 companies
Healthcare provider profile · identity verified
Karen C Lee, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TEANECK, NJ · NPI 1780766857
Verified facts
What the public records show
CMS Open Payments records show Karen C Lee, MD received $151.13 in general payments during 2025 across 9 reported records.
Exact Sciences Corporation accounted for 24.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.77 | 24.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.85 | 23.1% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $30.91 | 20.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.51 | 14.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.56 | 9.0% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.53 | 8.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $151.13 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.85 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $30.91 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 484 | 93 |
| Tamsulosin Hcl | Tamsulosin Hcl | 305 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 273 | 60 |
| Eliquis | Apixaban | 241 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 228 | 32 |
| Lisinopril | Lisinopril | 205 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 196 | 47 |
| Donepezil Hcl | Donepezil Hcl | 183 | 23 |
| Simvastatin | Simvastatin | 174 | 26 |
| Omeprazole | Omeprazole | 173 | 23 |
| Sertraline Hcl | Sertraline Hcl | 173 | 21 |
| Metformin Hcl | Metformin Hcl | 167 | 29 |
| Losartan Potassium | Losartan Potassium | 163 | 32 |
| Gabapentin | Gabapentin | 143 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 130 | 28 |
| Furosemide | Furosemide | 122 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 110 | 15 |
| Finasteride | Finasteride | 107 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | suppressed |
| Memantine Hcl | Memantine Hcl | 98 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 11 |
| Carvedilol | Carvedilol | 88 | 13 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 87 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 21 |
| Warfarin Sodium | Warfarin Sodium | 85 | suppressed |
| Mirtazapine | Mirtazapine | 77 | 16 |
| Xarelto | Rivaroxaban | 77 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 12 |
| Potassium Chloride | Potassium Chloride | 69 | 17 |
| Latanoprost | Latanoprost | 68 | 11 |
| Buspirone Hcl | Buspirone Hcl | 66 | suppressed |
| Famotidine | Famotidine | 66 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 21 |
| Glipizide | Glipizide | 63 | 14 |
| Baclofen | Baclofen | 62 | 11 |
| Divalproex Sodium | Divalproex Sodium | 62 | 18 |
| Trazodone Hcl | Trazodone Hcl | 60 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 59 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 58 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | suppressed |
| Nystatin | Nystatin | 55 | 24 |
| Montelukast Sodium | Montelukast Sodium | 54 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Januvia | Sitagliptin Phosphate | 53 | suppressed |
| Levetiracetam | Levetiracetam | 53 | suppressed |
| Alprazolam | Alprazolam | 46 | 22 |
| Pregabalin | Pregabalin | 45 | suppressed |
| Lorazepam | Lorazepam | 44 | 15 |
| Ssd | Silver Sulfadiazine | 39 | 12 |
| Mupirocin | Mupirocin | 38 | 18 |
| Ibuprofen | Ibuprofen | 37 | suppressed |
| Torsemide | Torsemide | 36 | 11 |
| Silver Sulfadiazine | Silver Sulfadiazine | 35 | 16 |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 33 | 13 |
| Midodrine Hcl | Midodrine Hcl | 32 | suppressed |
| Acarbose | Acarbose | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Allopurinol | Allopurinol | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 12 |
| Memantine Hcl Er | Memantine Hcl | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Prednisone | Prednisone | 27 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 13 |
| Trulicity | Dulaglutide | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Cyclosporine | Cyclosporine | 24 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 24 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 24 | 19 |
| Silodosin | Silodosin | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 18 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 23 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 23 | 22 |
| Hydromorphone Hcl | Hydromorphone Hcl | 22 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Acetazolamide | Acetazolamide | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 13 |
| Atomoxetine Hcl | Atomoxetine Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 18 | 14 |
| Amoxicillin | Amoxicillin | 18 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Travoprost | Travoprost | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Dexamethasone | Dexamethasone | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Modafinil | Modafinil | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 13 | 13 |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Metaxalone | Metaxalone | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $151.13 · 9 records | Exact Sciences Corporation | AUSTEDO XR, Belbuca, Cologuard Collection Kit, FARXIGA, REXULTI, The Cologuard Plus Collection Kit, WATCHMAN Access System | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error